Appln. No. 09/756,185

Amdt. dated March 17, 2004

Reply to Office action of December 17, 2003

Amendments to the Claims:

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

- 1-2 (Cancelled)
- 3 (Previously Presented). A pharmaceutical composition comprising Component B and a human growth factor as active principles in combination with a pharmaceutically acceptable carrier.
- 4 (Previously Presented). The pharmaceutical composition according to Claim 3 wherein the two active principles are present in a single administration dose.
 - 5 (Cancelled)
- 6 (Previously Presented). The pharmaceutical composition according to Claim 3 wherein the human growth factor is bFGF or VEGF.
 - 7-9 (Cancelled)
- 10 (Previously Presented). The pharmaceutical composition according to Claim 4 wherein the human growth factor is bFGF or VEGF.
- 11 (Previously Presented). A method of promoting angiogenesis in a patient in need thereof, comprising administering Component B and a human growth factor to the patient for a time sufficient and in an amount effective for the promotion of angiogenesis in the patient.

Appln. No. 09/756,185 Amdt. dated March 17, 2004 Reply to Office action of December 17, 2003 12 (Previously Presented). The method of Claim 11, wherein the angiogenesis is in relation to the treatment of a wound, ulcer or other traumatic lesion to the tissues of the body of the patient. 13 (Previously Presented). The method of claim 11, wherein the Component B and the human growth factor are administered in a single composition. 14 (Previously Presented). The method of claim 12, wherein the Component B and the human growth factor are administered in a single composition. 15 (Previously Presented). The method of claim 11, wherein the Component B and the human growth factor are administered in separate compositions. 16 (Previously Presented). The method of claim 12, wherein the Component B and the human growth factor are administered in separate compositions. 17 (Previously Presented). The method of claim 11, wherein the human growth factor is bFGF or VEGF. 18 (Previously Presented). The method of claim 12, wherein the human growth factor is bFGF or VEGF. 19 (Currently Amended). The method of claim 11, wherein the relative amounts ratio of the amount of Component B and to the amount of the human growth factor are is selected to provide synergistic angiogenesis results. - 3 -

Appln. No. 09/756,185 Amdt. dated March 17, 2004 Reply to Office action of December 17, 2003 20 (Previously Presented). A method of treating a wound, ulcer or other traumatic lesion in a patient in need thereof, comprising administering Component B and a human growth factor to the patient for a time sufficient and in an amount effective for the treatment of the wound, ulcer or other traumatic lesion in the patient. 21 (Previously Presented). The method of claim 20, wherein the Component B and the human growth factor are administered in separate administration doses. 22 (Previously Presented). The method of claim 20, wherein the human growth factor is bFGF or VEGF. 23. (Currently Amended). The method of claim 20, wherein the ratio relative amounts of the amount of Component B and to the amount of the human growth factor are is selected to provide synergistic results. 24 (Previously Presented). A pharmaceutical composition for use in the promotion of angiogenesis, comprising Component B and a human growth factor as active principles in combination with a pharmaceutically acceptable carrier, wherein the relative amounts of Component B and the human growth factor are selected to provide synergistic angiogenesis results when administered to a patient in need thereof. 25 (Previously Presented). A pharmaceutical composition for use in the treatment of a wound, ulcer or - 4 -

Appln. No. 09/756,185 Amdt. dated March 17, 2004 Reply to Office action of December 17, 2003

other traumatic lesion, comprising Component B and a human growth factor as active principles in combination with a pharmaceutically acceptable carrier, wherein the relative amounts of Component B and the human growth factor are selected to provide synergistic results when administered to a patient in need thereof.